Leading Regenerative Veterinary Medicine Company, VetStem Biopharma, announces the addition of Dr. Mark Hughes as the Senior Manager, Veterinary Clinical Research and Safety.

Poway, CA (PRWEB) June 20, 2016

VetStem Biopharma proudly announces Dr. Mark Hughes as the Senior Manager, Veterinary Clinical Research and Safety. Dr. Hughes, former Product Development Manager in R&D at Virbac Corporation, brings eight years of experience managing drug development projects through the process of pharmaceutical development, preclinical and clinical trials, and submissions to regulatory authorities for marketing approval in the US and Canada. Dr. Hughes received BS, MS, and DVM degrees from the University of California, Davis, and is licensed to practice in California. He also has provided commercial embryo transfer services for beef and dairy cattle, developed in-vitro diagnostics for diseases in animals and people, and managed a laboratory animal research facility.

“With 8 years of experience in the veterinary product development market and having extensive experience in clinical field trials Dr. Hughes will be a great addition to our team.” Dr. Robert Harman, CEO, explains. “Dr. Hughes will be responsible for the continued development of new services, products and clinical data generation. We believe with his previous history and understanding of the product development process, he will efficiently guide our projects through the FDA approval process.”

“I am very pleased to join the VetStem Biopharma team to be an integral part of a dynamic, industry-leading company in a field with breakthrough potential for treating a diverse range of diseases and injuries in companion animals and horses,” said Dr. Hughes. “I am excited to participate in the development of products that truly will benefit our animal friends worldwide.”

advertisement | advertise on newsday

VetStem is currently in the product development phase for the first off-the-shelf stem cell product for the canine osteoarthritis. As many as two thirds of dogs over 7 years old are affected by osteoarthritis, which has created the largest existing market segment in pet therapeutics. Although currently marketed products can help decrease the crippling symptoms of osteoarthritis, they are not designed to regenerate and heal the damaged tissue that is causing pain. Regenerative medicine focuses on true regeneration of damaged tissues and organs.

About VetStem Biopharma
VetStem Biopharma is a veterinarian-lead company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 14 years and 12,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The company’s stated mission being “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases”. In addition to its’ own portfolio of patents, VetStem holds exclusive global veterinary licenses to a portfolio of over 55 issued patents in the field of regenerative medicine.

For the original version on PRWeb visit: http://www.prweb.com/releases/2016/06/prweb13467382.htm